Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery
A Phase 1 Study of BLZ-100 Administered by Intravenous Injection in Subjects With Soft Tissue Sarcoma Undergoing Surgery
연구 개요
상세 설명
Subjects who provide voluntary written informed consent will be screened for eligibility. Subjects meeting all of the inclusion and none of the exclusion criteria will be eligible to participate.
This is a two part study:
Part 1 - Dose Finding: Subjects will be required to arrive at the phase 1 unit for dosing 2-3 days prior to the planned surgical excision. Two dose levels of BLZ-100 (3 mg and 12 mg) will be evaluated in a total of 6 subjects with a 2-3 day post-dose imaging interval (also defined as the Intermediate Imaging interval).
Part 2 - Imaging Interval Assessment: The BLZ-100 dose to be evaluated in Part 2 will be determined by the Protocol Steering Committee following completion of Part 1. In Part 2, up to 15 additional subjects will be randomized into one of three imaging interval groups (up to 6 subjects per group): Early Imaging (within 1 day post BLZ-100 dose), Intermediate Imaging (2-3 days post BLZ-100 dose), and Late Imaging (4-7 days post BLZ-100 dose). Subjects will be required to arrive at the phase 1 unit for dosing between 1 and 7 days prior to planned surgical excision, depending on which imaging interval they are randomized to.
Following dosing, all subjects will be monitored for safety.
연구 유형
단계
- 1단계
연락처 및 위치
연구 장소
-
-
California
-
Los Angeles, California, 미국, 90048
- Cedars-Sinai Medical Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Male of female subject aged 18-75 years
- Diagnosis of soft tissue sarcoma, with scheduled surgical removal for treatment for the disease and completion of chemotherapy or radiation within 4 weeks of BLZ-100 administration
- Able to provide written informed consent
- If of child-bearing potential, agree to continued use of two reliable methods of contraceptive from study entry (time of informed consent) through 30 days after BLZ-100 administration
- Available for all study visits and able to comply with all study requirements
Exclusion Criteria:
- Clinically-suspected and/or pathologically-confirmed sarcoma of the bone (e.g. osteosarcoma, Ewing's sarcoma with bony involvement, chondrosarcoma, Kaposi's sarcoma, extraosseous primitive neuroectodermal tumor [PNET])
- Evidence of metastatic disease
- Female who is lactating/breastfeeding
- Female with a positive pregnancy test or who is planning to become pregnant during the duration of the study
- Karnofsky Performance Status of <60%
Any of the following laboratory abnormalities at Screening:
- Neutrophil count <1.5 x 10^9/L
- Platelets <75 x 10^9/L
- Hemoglobin <10 g/dL (may be determined following transfusion)
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3x upper limit of normal (ULN)
- Total bilirubin >1.5x upper limit of reference range (unless Gilbert's syndrome or extrahepatic source as denoted by increased indirect bilirubin fraction)
- Internal Normalized Ratio (INR) >1.5
- Creatinine >1.5x ULN
- Calculated estimated glomerular filtration rate (eGFR) ≤60 mL/min
- Positive serology for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV)
- QTc prolongation >450 msec
- History of hypersensitivity or allergic reactions requiring corticosteroids, epinephrine, and/or hospitalization
- Uncontrolled asthma or asthma requiring oral corticosteroids
- Known or suspected sensitivity to imaging agents that may be used in clinical assessment of this study
- Known or suspected sensitivity to indocyanine green (ICG)
- Unstable angina, myocardial infarction, known or suspected transient ischemic events, or stroke within 24 weeks of start of Screening
- Uncontrolled hypertension
- Initiation of new photosensitizing drugs within 30 days of Screening
- Use of any ongoing medications, which might generate fluorescence or, according to the medication label, might generate a photochemical reaction. These include haematoporphyrin derivatives and purified fractions, Photofrin®, and the precursors of protoporphyrin IX (5-Aminolevulinic acid) used in Gliolan or Hexvix
- Receipt of an investigational drug or device within 30 days of enrollment
- Prior administration of BLZ-100
- Any concurrent condition, including psychological and social situations, which, in the opinion of the investigator, would adversely impact the subject or the interpretation of the study data
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: BLZ-100
All participants in the study will receive the investigational drug product BLZ-100. In part 1 of the study, two dose levels of BLZ-100 will be evaluated (3 mg and 12 mg) in 6 subjects, with a 2-3 post-dose imaging window. In part 2 of the study up to 15 additional subjects will be randomized to one of three imaging interval groups (up to 6 subjects/interval): Early Imaging (within 1 day post-BLZ-100 dose), Intermediate Imaging (2 - 3 days post- BLZ-100 dose), and Late Imaging (4 - 7 days post- BLZ-100 dose). |
All subjects enrolled in the study will receive doses of BLZ-100, an investigational drug for imaging tumors. Three different imaging windows will be investigated during the study: Early Imaging (imaging occurs within 1 day post-BLZ-100 dose); Intermediate Imaging (imaging occurs within 2-3 days post-BLZ-100 dose); Late Imaging (imaging occurs 4-7 post-BLZ-100 dose) All subjects in Part 1 of the study will be imaged in the Intermediate Imaging group. Subjects in Part 2 of the study will be randomized into one of the three imaging groups.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
부작용이 있는 참가자 수
기간: 연구 약물 투여 후 7일
|
안전성은 신체 검사와 활력 징후 및 실험실 안전 매개변수의 측정으로 평가됩니다.
|
연구 약물 투여 후 7일
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change of concentration of BLZ-100 in the blood
기간: Prior to dosing and at 1 minute, 5 minutes, 15 minutes, 30 minutes, 60 minutes and 120 minutes after end of injection, and pre-surgery and 24 hours post-surgery
|
BLZ-100 levels in blood will be analyzed by chemical means and these data will be used to calculate pharmacokinetic parameters.
|
Prior to dosing and at 1 minute, 5 minutes, 15 minutes, 30 minutes, 60 minutes and 120 minutes after end of injection, and pre-surgery and 24 hours post-surgery
|
|
Fluorescence signal from areas of tumor and non-tumor
기간: 1 day post-dose, 2-3 days post-dose, or 3-7 days post-dose
|
Fluorescent signal in sections of excised tumor and adjacent normal tissue will be measured using an infrared imaging system.
|
1 day post-dose, 2-3 days post-dose, or 3-7 days post-dose
|
|
Ideal combination of dose and imaging interval
기간: 1 day post-dose, 2-3 days post-dose, 3-7 days post-dose
|
Fluorescent signal will be evaluated in sections of excised tumor and adjacent normal tissue to determine which imaging interval provides the optimal images.
|
1 day post-dose, 2-3 days post-dose, 3-7 days post-dose
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Charles Forscher, MD, Cedars-Sinai Medical Center
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- BB-003
- 261201400046C-0-0-1 (미국 NIH 보조금/계약)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
육종, 연조직에 대한 임상 시험
-
Kirsehir Ahi Evran Universitesi모병
BLZ-100에 대한 임상 시험
-
Blaze Bioscience Inc.Pacific Pediatric Neuro-Oncology Consortium완전한
-
University of WashingtonBlaze Bioscience Inc.모병3기 입술 및 구강암 AJCC v8 | 구강 편평 세포 암종 | 1기 입술 및 구강암 AJCC v8 | 2기 입술 및 구강암 AJCC v8 | IVA기 입술 및 구강암 AJCC v8미국
-
National Heart, Lung, and Blood Institute (NHLBI)완전한심근 경색증 | 심근 허혈 | 심장 질환 | 심혈관 질환 | 관상 동맥 질환
-
OrthoTrophix, Inc완전한